Evidence map›Paper›PMID 29748135›Full record

ArticleCell calcium2018

Oncogenic KRAS suppresses store-operated Ca

Cristina Pierro, Xuexin Zhang, Cynthia Kankeu, Mohamed Trebak, Martin D Bootman, H Llewelyn Roderick

Open access · greenAbstract read
In one paragraph

Article in Cell calcium, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Driver Mutations of Pancreatic Cancer Affect CaFunction (Oxford, England) · 2023
    Article
  2. Article
  3. Review
  4. Ion Channels in Lung Cancer.Reviews of physiology, biochemistry and pharmacology · 2021
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. The Calcium-Signaling Toolkit in Cancer: Remodeling and Targeting.Cold Spring Harbor perspectives in biology · 2019
    Review
  10. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Cristina PierroLaboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; Previously at Babraham Institute, Babraham Research Campus, Cambridge, UK.
Xuexin ZhangDepartment of Cellular and Molecular Physiology and Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey PA 17033, United States.
Cynthia KankeuLaboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Mohamed TrebakDepartment of Cellular and Molecular Physiology and Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey PA 17033, United States.
Martin D BootmanPreviously at Babraham Institute, Babraham Research Campus, Cambridge, UK; School of Life, Health and Chemical Sciences, The Open University, UK.
H Llewelyn RoderickLaboratory of Experimental Cardiology, Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium; Previously at Babraham Institute, Babraham Research Campus, Cambridge, UK. Electronic address: llewelyn.roderick@kuleuven.be.
Babraham Institute · GBPenn State Milton S. Hershey Medical Center · USKU Leuven · BE

Funding

Receptor-regulated Ca2+ Entry Pathways in Smooth MuscleR01HL097111 · NHLBI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI TREBAK, MOHAMED · 2010 to 2019
$3.7M
Leukotriene C4 and STIM/Orai channels in airway smooth muscle remodelingR01HL123364 · NHLBI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI TREBAK, MOHAMED · 2014 to 2017
$1.5M
Genes and miRNAs controlled by ORAI3 in cardiovascular remodelingR21AG050072 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEBECHE, DJAMEL, TREBAK, MOHAMED · 2016 to 2017
$471k
Biotechnology and Biological Sciences Research Council BBS/E/B/0000H110NHLBI NIH HHS R01 HL097111NHLBI NIH HHS R01 HL123364NIA NIH HHS R21 AG050072
6 · The paper itself

Abstract

The KRAS GTPase plays a fundamental role in transducing signals from plasma membrane growth factor receptors to downstream signalling pathways controlling cell proliferation, survival and migration. Activating KRAS mutations are found in 20% of all cancers and in up to 40% of colorectal cancers, where they contribute to dysregulation of cell processes underlying oncogenic transformation. Multiple KRAS-regulated cell functions are also influenced by changes in intracellular Ca

Indexed as

Calcium SignalingIon Channel GatingMAP Kinase Signaling SystemOncogenesBenzamidesCell Line, TumorColorectal NeoplasmsHumansMitogen-Activated Protein Kinase KinasesNeoplasm ProteinsProto-Oncogene Proteins p21(ras)Recombinant Fusion ProteinsStromal Interaction Molecule 1Stromal Interaction Molecule 22-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamideBenzamidesKRAS protein, humanMitogen-Activated Protein Kinase KinasesNeoplasm ProteinsProto-Oncogene Proteins p21(ras)Recombinant Fusion ProteinsSTIM1 protein, humanSTIM2 protein, humanStromal Interaction Molecule 1Stromal Interaction Molecule 2Calcium signallingColorectal cancerERKKRASSOCE/I(CRAC)STIM

Identifiers

PMID29748135
PMCPMC6291847
OpenAlexW2791344026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.